A chemotherapy response prediction model derived from tumor-promoting B and Tregs and proinflammatory macrophages in HGSOC
BackgroundMost patients with high-grade serous ovarian cancer (HGSOC) experienced disease recurrence with cumulative chemoresistance, leading to treatment failure. However, few biomarkers are currently available in clinical practice that can accurately predict chemotherapy response. The tumor immune...
Main Authors: | Yue Xi, Yingchun Zhang, Kun Zheng, Jiawei Zou, Lv Gui, Xin Zou, Liang Chen, Jie Hao, Yiming Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1171582/full |
Similar Items
-
The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction
by: Racheal Louise Johnson, et al.
Published: (2021-12-01) -
Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
by: Lu Zhang, et al.
Published: (2021-11-01) -
Establishment of a prognostic model for ovarian cancer based on mitochondrial metabolism-related genes
by: Chao Meng, et al.
Published: (2023-05-01) -
Integrated analysis of scRNA-seq and bulk RNA-seq identifies FBXO2 as a candidate biomarker associated with chemoresistance in HGSOC
by: Wenwen Lai, et al.
Published: (2024-04-01) -
Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance Treatment
by: Marcus Vetter, et al.
Published: (2022-11-01)